MCF2L

Across TCGA pan-cancer cohorts, MCF2L Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MCF2L data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher MCF2L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MCF2L expression acts as an unfavorable survival marker.

ACC, MESO, and SCLC are the cancer types where MCF2L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
MESO	DFS	Median	All	0.099	0.487	<.001	24	view →
SCLC	OS	Median	All	0.082	0.653	.002	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	DFS	Median	III,IV	0.206	0.670	.015	6	view →
SKCM	OS	Median	IV	0.226	0.613	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MCF2L–ACC (DFS)

Open the ACC breakdown →